BioCentury | Jun 21, 2017
Distillery Techniques

Drug delivery

...once-weekly exenatide, in Phase III testing for Type II diabetes. BMS and Alkermes also have Exenatide once monthly...
BioCentury | Jul 9, 2012
Strategy

Triple play in diabetes

The addition of Amylin Pharmaceuticals Inc. 's glucagon-like peptide 1 franchise will give partners Bristol-Myers Squibb Co. and AstraZeneca plc three modern mechanisms in their commercial diabetes portfolio and five in the pipeline - more than...
BioCentury | Jul 4, 2011
Clinical News

Exenatide once monthly: Additional Phase II data

...showed that 50%, 57% and 70% of patients receiving 5, 8 and 11 mg subcutaneous exenatide once monthly...
...48% for 2 mg subcutaneous Bydureon exenatide once weekly . Additionally, low-, mid- and high-dose exenatide once monthly...
...Diabetes Association meeting in San Diego. The partners previously reported that low-, mid- and high-dose exenatide once monthly...
BioCentury | Mar 14, 2011
Finance

Still some pop in Benlysta

...off $0.18 to $12.40, after the partners reported that low, mid- and high doses of exenatide once monthly...
BioCentury | Mar 14, 2011
Finance

Highlights of weekly biotech stock moves

...off $0.18 to $12.40, after the partners reported that low, mid- and high doses of exenatide once monthly...
BioCentury | Mar 14, 2011
Clinical News

Exenatide once monthly: Phase II data

...Phase II trial in 121 Type II diabetics showed that low-, mid- and high-dose subcutaneous exenatide once monthly...
...for 2 mg subcutaneous Bydureon exenatide once weekly . The most common adverse events for exenatide once monthly...
...said it plans to meet with regulatory authorities to discuss the next steps for the exenatide once monthly...
BioCentury | Mar 11, 2011
Clinical News

Amylin, partners report exenatide once monthly data

...Pharmaceuticals Inc. (NASDAQ:AMLN) and Eli Lilly and Co. (NYSE:LLY) said low-, mid- and high-doses of exenatide once monthly...
BioCentury | Oct 25, 2010
Regulation

Haunted by Byetta

...Amylin Pharmaceuticals Inc. (NASDAQ:AMLN)/Alkermes Inc. (NASDAQ:ALKS)/Eli Lilly and Co. (NYSE:LLY) Once-monthly exenatide Once-monthly formulation of exenatide Once monthly...
Items per page:
1 - 8 of 8